ASCO 2018 NSCLC highlights—combination therapy is key

Non-small cell lung cancer (NSCLC) treatment was booming at this year’s ASCO 2018 meeting as several well-performed phase III trials with practice-changing potential were presented. Thereby immune checkpoint blockade (ICB) consolidated its major role in the treatment of NSCLC patients without geneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamerith, Gabriele, Kocher, Florian, Rudzki, Jakob, Pircher, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280781/
https://www.ncbi.nlm.nih.gov/pubmed/30595752
http://dx.doi.org/10.1007/s12254-018-0444-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280781/
https://www.ncbi.nlm.nih.gov/pubmed/30595752
http://dx.doi.org/10.1007/s12254-018-0444-7

Ejemplares similares